Previous 10 | Next 10 |
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY s...
2023-08-15 11:40:24 ET Summary Generating high yields while taking on less market risk is possible. Our Advanced cash covered put selling strategy can generate high double-digit yields with being very conservative with risk. I believe that selling put options capitalizes on ma...
2023-08-10 09:53:00 ET There are a number of famous figures in the world of investing, and sometimes, looking to those people for inspiration on what stocks to buy can be a great idea. One of these famous names is Cathie Wood, CEO of the management firm Ark Invest. Wood and her team have bu...
CALGARY, AB / ACCESSWIRE / August 10, 2023 / Gamehost Inc. (TSX:GH) (" Gamehost " or the " Corporation ") announces that the Toronto Stock Exchange (" TSX ") has accepted Gamehost's Notice of Intention to Make a Normal Course Issuer Bid (the " Bid ") to purchase for cancellation, from time to ti...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / August 8, 2023 / Gamehost Inc. (TSX:GH) Management and Directors of Gamehost Inc. (the "Company") present results for the six and three months ended June 30, 2023 (the "Perio...
2023-08-03 23:57:11 ET Guardant Health, Inc. (GH) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Michael Bell - CF...
2023-08-03 16:17:40 ET Guardant Health press release ( NASDAQ: GH ): Q2 Non-GAAP EPS of -$0.82 beats by $0.11 . Revenue of $137.2M (+25.8% Y/Y) beats by $7.78M . Guardant Health now expects full year 2023 revenue to be in the range of $545 to $550 million, vs. ...
Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary...
2023-08-01 17:55:08 ET Guardant Health ( NASDAQ: GH ) said it has entered into an agreement with Illumina ( NASDAQ: ILMN ) that resolves their pending litigation and extends their commercial relationship. Under the agreement , the companies will ask the court to dism...
Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companie...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...